Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Anelixis_Therapeutics
|
| gptkbp:focusesOn |
otology
ear, nose, and throat disorders allergy-related diseases |
| gptkbp:founded |
2009
|
| gptkbp:headquartersLocation |
Irvine, California, United States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Novus Therapeutics, Inc.
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:keyPerson |
gptkb:Gregory_J._Flesher
|
| gptkbp:product |
OP0201
OP0101 |
| gptkbp:renamed |
Eledon Pharmaceuticals, Inc.
|
| gptkbp:tradedOn |
NASDAQ: NVUS
|
| gptkbp:website |
https://www.novustherapeutics.com/
|
| gptkbp:bfsParent |
gptkb:NVUS
|
| gptkbp:bfsLayer |
8
|